Antipyretic Drugs for Children Market
Antipyretic Drugs for Children Market Size, Share & Trends Analysis Report by Type (Paracetamol, Aspirin, Ibuprofen, Naproxen, and Diclofenac), by Application (Fever Reduction, Pain Relief, Common Cold and Flu Symptoms, And Others), and by Formulation (Liquid Suspensions, Chewable Tablets, Dissolvable Tablets, Suppositories, and Oral Powders)T)Forecast Period (2023-2030) Update Available - Forecast 2024-2030
Antipyretic drugs for children market is anticipated to grow at a considerable CAGR of 5.5% during the forecast period.The primary factor driving the growth of the market includesthe increasing prevalence of infectious diseases in children. Infectious diseases are a major cause of morbidity and mortality in children globally. According to the World Health Organization (WHO), pneumonia is the single largest infectious cause of fatalityin children globally. Pneumonia killed 740,180 children under the age of 5 in 2019, accounting for 14.0% of all deaths of children under 5 years old. Pneumonia is the leading cause of death in children under the age of five, followed by diarrheal diseases and malaria. These diseases cause fever, which is a common symptom. Antipyretic drugs are used to reduce fever and improve the comfort of children suffering from infectious diseases.The market is also driven by the availability of a wide range of antipyretic drugs in the market. There are several different antipyretic drugs available, including acetaminophen, ibuprofen, and naproxen. These drugs are available in a variety of dosage forms, including tablets, capsules,liquids, and suppositories. This variety of dosage forms makes it easy for parents to find an antipyretic drug that is appropriate for their child.
Segmental Outlook
The global antipyretic drugs for children market is segmented based on type, and application. Based on type, the market is bifurcated into paracetamol, aspirin, ibuprofen, naproxen, and diclofenac. By application, the market is bifurcated into fever reduction, pain relief, common cold and flu symptoms, and others. Further, by formulation, the market is sub-segmented into liquid suspensions, chewable tablets, dissolvable tablets, suppositories, and oral powders. Among these, the oral powders sub-segment accounted for the dominant share of the market during the forecast period.This is attributed to factors including ease of administration and accurate dosage, enhanced absorption, and flexibility in dosage strengths.
Paracetamol Sub-Segment is Anticipated to Hold a Prominent Share of the Global Antipyretic Drugs for Children Market
The growth is primarily fueled by the increasing incidence of fever among children, rising awareness about the benefits of antipyretic drugs for children, and growing demand for over the counter (OTC) antipyretic drugs for children. Additionally,the increased production of paracetamol through local market players and initiatives to encourage availability is expected to drive sub-segment growth over the forecast period. For instance, in June 2021, SEQENS officially launched the project to build a new paracetamol production unit in partnership with Sanofi and UPSA and with the support of the France Reliance program. It also reported that the unit will have a capacity for production of 10,000 tonnes of paracetamol per year. Painkillers such as acetaminophen (paracetamol) can relieve cold-related symptoms such as headaches, and joint pain. These painkillers can also lower a fever. The approval of such drugs by the regulatory authority is also propelling the growth of the sub-segment. For instance, in February 2020, GlaxoSmithKline received approval from the U.S. Food and Drug Administration (FDA) for Advil Dual Action with Acetaminophen as an OTC product for pain relief.
Regional Outlook
The global antipyretic drugs for childrenmarket is further segmented based on geography including North America (the US and Canada), Europe (UK, Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East and Africa, and Latin America). Among these, the Asia-Pacific region is projected to expand at a significant CAGR during the forecast period, due to the rising prevalence of fever-related illnesses, improved healthcare infrastructure, coupled with the government initiatives and policies.
Global Antipyretic Drugs for Children Market Growth, by Region 2023-2030
The North American Region is Anticipated to Hold a Significant Share of the Global Antipyretic Drugs for Children Market
The market growth is due to factors such as the presence of key players, the established healthcare infrastructure, and government initiatives.For instance, according to the National Institute of Health (NIH), the USgovernment spent $689.0 million in 2020 and $725.0 million in 2021 for research on chronic pain. Since paracetamol is largely used as a pain killer, increasing research on chronic pain is expected to boost the growth of the market.Additionally, in November 2021, the US FDA accepted the NDA for Maxigesic IV by Hyloris Pharmaceuticals SA. It is a unique combination of 1000 mg paracetamol and 300mg ibuprofen solution for infusion for the treatment of postoperative pain. Such application acceptance by the regulatory authorities may lead to the entrance of new products into the market in the future which will further propel the market growth in the region.
Market Players Outlook
The major companies serving the global antipyretic drugs for childrenmarket include GSK plc, Johnson & Johnson Services, Inc., and Pfizer Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, funding, collaborations, and new product launches to stay competitive in the market. For instance, in April 2022,IOL Chemicals and Pharmaceuticals started commercial production of paracetamol with an installed capacity of 1800 MTPA and backward integration of Para Amino Phenol (PAP).In August 2021, Philip Morris International (PMI), Inc., a US-based tobacco company,acquired OtiTopic for an undisclosed amount. This acquisition is a part of PMI'sstrategic objective to expand its pipeline of inhaled therapies and respiratory medication. OtiTopic is a US-based respiratory drug developmentcompany with a late-stage inhalable acetylsalicylic acid (ASA) treatment for acutemyocardial infarction. OtiTopic is a developer of an inhaled formulation of aspirindry powder.
The Report Covers
- Market value data analysis of 2022 and forecast to 2030.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global antipyretic drugs for children market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.2. GSK plc
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. Johnson & Johnson Services, Inc.
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
3.4. Pfizer Inc.
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5. Key Strategy Analysis
4. Market Segmentation
4.1. Global Antipyretic Drugs for ChildrenMarket by Type
4.1.1. Paracetamol (Acetaminophen)
4.1.2. Aspirin
4.1.3. Ibuprofen
4.1.4. Naproxen
4.1.5. Diclofenac
4.2. Global Antipyretic Drugs for Children Market by Application
4.2.1. Fever Reduction
4.2.2. Pain Relief
4.2.3. Common Cold and Flu Symptoms
4.2.4. ) Others( Tonsillitis, Pharyngitis)
4.3. Global Antipyretic Drugs for Children Market by Formulation
4.3.1. Liquid suspensions
4.3.2. Chewable tablets
4.3.3. Dissolvable tablets
4.3.4. Suppositories
4.3.5. Oral powders
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Anhui BBCA Likang Pharmaceutical Co., Ltd.
6.2. Anhui Fubore Pharmaceutical & Chemical Co. Ltd.
6.3. AnqiuLU’ANPharmaceutical Co., Ltd.
6.4. Atabay Kimya San. ve Tic. A.?.
6.5. Boehringer Ingelheim International GmbH
6.6. Farmson Pharmaceutical Gujarat Pvt. Ltd.
6.7. Granules India Ltd.
6.8. Hebei Jiheng Pharmaceutical Co., Ltd
6.9. Huzhou Konch Pharmaceutical Co., Ltd.
6.10. Mallinckrodt Pharmaceuticals
6.11. Novacy Inc
6.12. Zhejiang Kangle Pharmaceutical Company Ltd
1. GLOBAL ANTIPYRETIC DRUGS FOR CHILDRENMARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
2. GLOBAL PARACETAMOL AS ANTIPYRETIC DRUGS FOR CHILDRENMARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
3. GLOBAL ASPIRIN AS ANTIPYRETIC DRUGS FOR CHILDRENMARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
4. GLOBAL IBUPROFEN AS ANTIPYRETIC DRUGS FOR CHILDRENMARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
5. GLOBAL NAPROXEN AS ANTIPYRETIC DRUGS FOR CHILDRENMARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
6. GLOBAL DICLOFENAC AS ANTIPYRETIC DRUGS FOR CHILDRENMARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
7. GLOBAL ANTIPYRETIC DRUGS FOR CHILDREN MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
8. GLOBAL FEVER REDUCTION ANTIPYRETIC DRUGS FOR CHILDREN MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
9. GLOBAL PAIN RELIEF ANTIPYRETIC DRUGS FOR CHILDREN MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
10. GLOBAL COMMON COLD AND FLU SYMPTOMSANTIPYRETIC DRUGS FOR CHILDREN MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
11. GLOBAL OTHERS ANTIPYRETIC DRUGS FOR CHILDREN MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
12. GLOBAL ANTIPYRETIC DRUGS FOR CHILDREN MARKET RESEARCH AND ANALYSIS BY FORMULATION, 2022-2030 ($ MILLION)
13. GLOBAL LIQUID SUSPENSIONS ANTIPYRETIC DRUGS FOR CHILDREN MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
14. GLOBAL CHEWABLE TABLETS ANTIPYRETIC DRUGS FOR CHILDREN MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
15. GLOBAL DISSOLVABLE TABLETS ANTIPYRETIC DRUGS FOR CHILDREN MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
16. GLOBAL SUPPOSITORIES ANTIPYRETIC DRUGS FOR CHILDREN MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
17. GLOBAL ORAL POWDERS ANTIPYRETIC DRUGS FOR CHILDREN MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
18.
19. , 2022-2030 ($ MILLION)
20. GLOBAL ANTIPYRETIC DRUGS FOR CHILDRENMARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
21. NORTH AMERICAN ANTIPYRETIC DRUGS FOR CHILDRENMARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
22. NORTH AMERICAN ANTIPYRETIC DRUGS FOR CHILDRENMARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
23. NORTH AMERICAN ANTIPYRETIC DRUGS FOR CHILDREN MARKET RESEARCH AND ANALYSIS BY APPLICATION , 2022-2030 ($ MILLION)
24. NORTH AMERICAN ANTIPYRETIC DRUGS FOR CHILDREN MARKET RESEARCH AND ANALYSIS BY FORMULATION , 2022-2030 ($ MILLION
25. EUROPEAN ANTIPYRETIC DRUGS FOR CHILDRENMARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
26. EUROPEAN ANTIPYRETIC DRUGS FOR CHILDRENMARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
27. EUROPEAN ANTIPYRETIC DRUGS FOR CHILDRENMARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
28. EUROPEAN ANTIPYRETIC DRUGS FOR CHILDREN MARKET RESEARCH AND ANALYSIS BY FORMULATION, 2022-2030 ($ MILLION)
29. ASIA-PACIFIC ANTIPYRETIC DRUGS FOR CHILDRENMARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
30. ASIA-PACIFIC ANTIPYRETIC DRUGS FOR CHILDRENMARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
31. ASIA-PACIFIC ANTIPYRETIC DRUGS FOR CHILDRENMARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
32. ASIA-PACIFIC ANTIPYRETIC DRUGS FOR CHILDRENMARKET RESEARCH AND ANALYSIS BY FORMULATION, 2022-2030 ($ MILLION)
33. REST OF THE WORLD ANTIPYRETIC DRUGS FOR CHILDRENMARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
34. REST OF THE WORLD ANTIPYRETIC DRUGS FOR CHILDRENMARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
35. REST OF THE WORLD ANTIPYRETIC DRUGS FOR CHILDRENMARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
36. REST OF THE WORLD ANTIPYRETIC DRUGS FOR CHILDRENMARKET RESEARCH AND ANALYSIS BY FORMULATION, 2022-2030 ($ MILLION)
1. GLOBAL ANTIPYRETIC DRUGS FOR CHILDREN MARKET SHARE BY TYPE, 2022 VS 2030 (%)
2. GLOBAL PARACETAMOL AS ANTIPYRETIC DRUGS FOR CHILDREN MARKET SHARE BY REGION, 2022 VS 2030 (%)
3. GLOBAL ASPIRIN AS ANTIPYRETIC DRUGS FOR CHILDRENMARKET SHARE BY REGION, 2022 VS 2030(%
4. GLOBAL IBUPROFEN AS ANTIPYRETIC DRUGS FOR CHILDREN MARKET SHARE BY REGION, 2022 VS 2030(%
5. GLOBAL NAPROXEN AS ANTIPYRETIC DRUGS FOR CHILDRENMARKET SHARE BY REGION, 2022 VS 2030(%
6. GLOBAL DICLOFENAC AS ANTIPYRETIC DRUGS FOR CHILDRENMARKET SHARE BY REGION, 2022 VS 2030(%
7. GLOBAL ANTIPYRETIC DRUGS FOR CHILDREN MARKET SHARE BY APPLICATION, 2022 VS 2030 (%)
8. GLOBAL FEVER REDUCTION ANTIPYRETIC DRUGS FOR CHILDREN MARKET SHARE BY REGION, 2022 VS 2030 (%)
9. GLOBAL PAIN RELIEF ANTIPYRETIC DRUGS FOR CHILDREN MARKET SHARE BY REGION, 2022 VS 2030 (%)
10. GLOBAL COMMON COLD AND FLU SYMPTOMS ANTIPYRETIC DRUGS FOR CHILDREN MARKET SHARE BY REGION, 2022 VS 2030 (%)
11. GLOBAL OTHERSANTIPYRETIC DRUGS FOR CHILDREN MARKET SHARE BY REGION, 2022 VS 2030 (%)
12. GLOBAL ANTIPYRETIC DRUGS FOR CHILDREN MARKET SHARE BY FORMULATION, 2022 VS 2030 (%)
13. GLOBAL LIQUID SUSPENSIONS ANTIPYRETIC DRUGS FOR CHILDREN MARKET SHARE BY REGION, 2022 VS 2030 (%)
14. GLOBAL CHEWABLE TABLETS ANTIPYRETIC DRUGS FOR CHILDREN MARKET SHARE BY REGION, 2022 VS 2030 (%)
15. GLOBAL DISSOLVABLE TABLETS ANTIPYRETIC DRUGS FOR CHILDREN MARKET SHARE BY REGION, 2022 VS 2030 (%)
16. GLOBAL SUPPOSITORIES DRUG ANTIPYRETIC DRUGS FOR CHILDREN MARKET SHARE BY REGION, 2022 VS 2030 (%)
17. GLOBAL ORAL POWDERS DRUG ANTIPYRETIC DRUGS FOR CHILDREN MARKET SHARE BY REGION, 2022 VS 2030 (%)
18. GLOBAL ANTIPYRETIC DRUGS FOR CHILDREN MARKET SHARE BY REGION, 2022 VS 2030 (%)
19. US ANTIPYRETIC DRUGS FOR CHILDRENMARKET SIZE, 2022-2030 ($ MILLION)
20. CANADA ANTIPYRETIC DRUGS FOR CHILDRENMARKET SIZE, 2022-2030 ($ MILLION)
21. UK ANTIPYRETIC DRUGS FOR CHILDRENMARKET SIZE, 2022-2030 ($ MILLION)
22. FRANCE ANTIPYRETIC DRUGS FOR CHILDRENMARKET SIZE, 2022-2030 ($ MILLION)
23. GERMANY ANTIPYRETIC DRUGS FOR CHILDRENMARKET SIZE, 2022-2030 ($ MILLION)
24. ITALY ANTIPYRETIC DRUGS FOR CHILDRENMARKET SIZE, 2022-2030 ($ MILLION)
25. SPAIN ANTIPYRETIC DRUGS FOR CHILDRENMARKET SIZE, 2022-2030 ($ MILLION)
26. REST OF EUROPE ANTIPYRETIC DRUGS FOR CHILDRENMARKET SIZE, 2022-2030 ($ MILLION)
27. INDIA ANTIPYRETIC DRUGS FOR CHILDRENMARKET SIZE, 2022-2030 ($ MILLION)
28. CHINA ANTIPYRETIC DRUGS FOR CHILDRENMARKET SIZE, 2022-2030 ($ MILLION)
29. JAPAN ANTIPYRETIC DRUGS FOR CHILDRENMARKET SIZE, 2022-2030 ($ MILLION)
30. SOUTH KOREA ANTIPYRETIC DRUGS FOR CHILDRENMARKET SIZE, 2022-2030 ($ MILLION)
31. REST OF ASIA-PACIFIC ANTIPYRETIC DRUGS FOR CHILDRENMARKET SIZE, 2022-2030 ($ MILLION)
32. REST OF THE WORLD ANTIPYRETIC DRUGS FOR CHILDRENMARKET SIZE, 2022-2030 ($ MILLION)
